Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Rapid eye movement sleep duration during the multiple sleep latency test to diagnose hypocretin-deficient narcolepsy

View through CrossRef
Abstract Study Objectives To assess the performances of alternative measures of the multiple sleep latency test (MSLT) to identify hypocretin-deficiency in patients with a complaint of hypersomnolence, including patients with narcolepsy. Methods MSLT parameters from 374 drug-free patients with hypersomnolence, with complete clinical and polysomnographic (PSG) assessment and cerebrospinal hypocretin-1 measurement were collected. Conventional (sleep latency, number of sleep onset REM—SOREM—periods) and alternative (sleep duration, REM sleep latency and duration, sleep stage transitions) MSLT measures were compared as function of hypocretin-1 levels (≤110 vs > 110 pg/mL). We performed receiver-operating characteristics analyses to determine the best thresholds of MSLT parameters to identify hypocretin-deficiency in the global population and in subgroups of patients with narcolepsy (i.e. typical cataplexy and/or positive PSG/MSLT criteria, n = 223). Results Patients with hypocretin-deficiency had shorter mean sleep and REM sleep latencies, longer mean sleep and REM sleep durations and more direct REM sleep transitions during the MSLT. The current standards of MSLT/PSG criteria identified hypocretin-deficient patients with a sensitivity of 0.87 and a specificity of 0.69, and 0.81/0.99 when combined with cataplexy. A mean REM sleep duration ≥ 4.1 min best identified hypocretin-deficiency in patients with hypersomnolence (AUC = 0.932, sensitivity 0.87, specificity 0.86) and ≥ 5.7 min in patients with narcolepsy (AUC = 0.832, sensitivity 0.77, specificity 0.82). Conclusion Compared to the current neurophysiological standard criteria, alternative MSLT parameters would better identify hypocretin-deficiency among patients with hypersomnolence and those with narcolepsy. We highlighted daytime REM sleep duration as a relevant neurophysiological biomarker of hypocretin-deficiency to be used in clinical and research settings.
Title: Rapid eye movement sleep duration during the multiple sleep latency test to diagnose hypocretin-deficient narcolepsy
Description:
Abstract Study Objectives To assess the performances of alternative measures of the multiple sleep latency test (MSLT) to identify hypocretin-deficiency in patients with a complaint of hypersomnolence, including patients with narcolepsy.
Methods MSLT parameters from 374 drug-free patients with hypersomnolence, with complete clinical and polysomnographic (PSG) assessment and cerebrospinal hypocretin-1 measurement were collected.
Conventional (sleep latency, number of sleep onset REM—SOREM—periods) and alternative (sleep duration, REM sleep latency and duration, sleep stage transitions) MSLT measures were compared as function of hypocretin-1 levels (≤110 vs > 110 pg/mL).
We performed receiver-operating characteristics analyses to determine the best thresholds of MSLT parameters to identify hypocretin-deficiency in the global population and in subgroups of patients with narcolepsy (i.
e.
typical cataplexy and/or positive PSG/MSLT criteria, n = 223).
Results Patients with hypocretin-deficiency had shorter mean sleep and REM sleep latencies, longer mean sleep and REM sleep durations and more direct REM sleep transitions during the MSLT.
The current standards of MSLT/PSG criteria identified hypocretin-deficient patients with a sensitivity of 0.
87 and a specificity of 0.
69, and 0.
81/0.
99 when combined with cataplexy.
A mean REM sleep duration ≥ 4.
1 min best identified hypocretin-deficiency in patients with hypersomnolence (AUC = 0.
932, sensitivity 0.
87, specificity 0.
86) and ≥ 5.
7 min in patients with narcolepsy (AUC = 0.
832, sensitivity 0.
77, specificity 0.
82).
Conclusion Compared to the current neurophysiological standard criteria, alternative MSLT parameters would better identify hypocretin-deficiency among patients with hypersomnolence and those with narcolepsy.
We highlighted daytime REM sleep duration as a relevant neurophysiological biomarker of hypocretin-deficiency to be used in clinical and research settings.

Related Results

Molecular mechanism of tumour necrosis factor alpha regulates hypocretin (orexin) expression, sleep and behaviour
Molecular mechanism of tumour necrosis factor alpha regulates hypocretin (orexin) expression, sleep and behaviour
Abstract Hypocretin 1 and hypocretin 2 (orexin A and B) regulate sleep, wakefulness and emotion. Tumour necrosis factor alpha (TNF‐α) is an important neuroinflamm...
Narcolepsy
Narcolepsy
Narcolepsy with and without cataplexy has two different nosological entities. Narcolepsy-cataplexy is strongly associated with HLA-DQB1*0602 and usually caused by a selective defic...
Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study
Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study
Abstract Study Objectives Narcolepsy is associated with cardiovascular risk factors; however, the risk of new-onset cardiovascul...
Narcolepsy: Neuropharmacological Aspects
Narcolepsy: Neuropharmacological Aspects
AbstractNarcolepsy (affects 1/2000 of the general population) is characterized by excessive daytime sleepiness, cataplexy, and other dissociated manifestations of rapid eye movemen...
The Relationship between Plasma Hypocretin Levels and Sleep Disorders in Patients with Parkinson's Disease
The Relationship between Plasma Hypocretin Levels and Sleep Disorders in Patients with Parkinson's Disease
Introduction: There are many areas of brain degeneration in people with Parkinson's disease. The dopaminergic degeneration process in the midbrain causes early symptoms of sleep di...
The Relationship between Plasma Hypocretin Levels and Sleep Disorders in Patients with Parkinson's Disease
The Relationship between Plasma Hypocretin Levels and Sleep Disorders in Patients with Parkinson's Disease
Introduction: There are many areas of brain degeneration in people with Parkinson's disease. The dopaminergic degeneration process in the midbrain causes early symptoms of sleep di...
Did Thomas Willis describe narcolepsy?
Did Thomas Willis describe narcolepsy?
Background: Narcolepsy is a disorder characterized by chronic daytime sleepiness, sudden sleep attacks and cataplexy. Westphal is often credited for first describing narcolepsy in ...
503 Cardio-Vascular Burden of Narcolepsy Disease (CV-BOND): a Real-World Evidence Study
503 Cardio-Vascular Burden of Narcolepsy Disease (CV-BOND): a Real-World Evidence Study
Abstract Introduction Narcolepsy is a rare, lifelong disorder that requires long-term treatment and is associated with multiple ...

Back to Top